Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease

Stem Cells

Volumn 26, Issue 10, 2008, Pages 2531-2541

  Li, Hong ^a   Guo, ZiKuan ^b   Jiang, XiaoXia ^a   Zhu, Heng ^a   Li, XiuSen ^a   Mao, Ning ^a,c  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c Department of Pharmacology   (China)

Author keywords

Acute graft versus host disease; Dendritic cells; Mesenchymal stem cell; Migration; T lymphocyte

Indexed keywords

CHEMOKINE RECEPTOR CCR7; L SELECTIN;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; DENDRITIC CELL; DISEASE COURSE; FEMALE; IN VITRO STUDY; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD; CDC42 GTP-BINDING PROTEIN; CELL MOVEMENT; COCULTURE TECHNIQUES; CYTOSKELETON; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; GRAFT VS HOST DISEASE; INFUSIONS, INTRAVENOUS; L-SELECTIN; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOID TISSUE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; ORGAN SPECIFICITY; RAC1 GTP-BINDING PROTEIN; RECEPTORS, CCR7; SPLEEN; SUBCELLULAR FRACTIONS; T-LYMPHOCYTES;

MURINAE; MUS;

EID: 55049140192     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0146     Document Type: Article

References (50)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-74.
2. Bianco P, Gehron Robey P. Marrow stromal stem cells. J Clin Invest 2000;105:1663-1668.
3. Peister A, Mellad JA, Larson BL et al. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004;103:1662-1668.
4. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
5. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843.
6. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-3729.
7. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005;105:4120-4126.
8. Sotiropoulou PA, Perez SA, Gritzapis AD et al. Interactions between human mesenchymal stem cells and natural killer cells. STEM CELLS 2006;24:74-85.
9. Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-372.
10. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-48.
11. Guo ZK, Li H, Li XS et al. In vitro characteristics and in vivo immunosuppressive activity of compact bone-derived murine mesenchymal progenitor cells. STEM CELLS 2006;24:992-1000.
12. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
13. Lazarus HM, Koc ON, Devine SM et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11:389-398.
14. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966-1967;62:21-78.
15. Sackstein R. A revision of Billingham's tenets: The central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 2006;12:2-8.
16. Kim YM, Sachs T, Asavaroengchai W et al. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003;111:659-669.
17. Kataoka H, Ohtsuki M, Shimano K et al. Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice. Transplant Proc 2005;37:107-109.
18. Hoffmann P, Ermann J, Edinger M et al. Donor-type CD4(+)CD25(+) regulatory T cells supress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-399.
19. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493-3499.
20. Trenado A, Sudres M, Tang Q et al. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006;176:1266-1273.
21. Mahnke K, Johnson TS, Ring S et al. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 2007;46:159-167.
22. Korngold R, Sprent J. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol 1985;135:3004-3010.
23. Liang S, Alard P, Zhao Y et al. Conversion of CD4-CD25+cells into CD4+CD25+regulatory T cells in vivo requires B7 costimulation, but not the thymus. JEM 2005;201:127-137.
24. Zhang MH, Tang H, Guo ZH et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol 2004;5:1124-1133.
25. Shi GX, Wu YL, Zhang J et al. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol 2003;171:3407-3414.
26. Li H, Guo ZK, Li XS et al. Functional and phenotypic alteration of intrasplenic lymphocytes affected by mesenchymal stem cells in a murine allo-splenocyte transfusion model. Cell Transplant 2007;16:85-95.
27. Leithäuser F, Trobonjaca Z, Reimann J et al. In situ characterization of genetically targeted (green fluorescent) single cells and their microenvironment in an adoptive host. Am J Pathol 2001;158:1975-1983.
28. Viola A, Contento LV, Molon B. T cells and their partners: The chemokine dating agency. Trends Immunol 2006;27:421-427.
29. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003;3:867-878.
30. Tapon N, Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 1997;9:86-92.
31. Benvenuti F, Hugues S, Walmsley M et al. Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science 2004;305:1150-1153.
32. Shurin GV, Tourkova IL, Chatta GS et al. Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol 2005;174:3394-4400.
33. Genot E, Reif K, Beach S et al. p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes. Oncogene 1998;17:1731-1738.
34. Palmeri D, van Zante A, Huang CC et al. Vascular endothelial junction-associated molecule, a novel member of the immunoglobulin superfamily, is localized to intercellular boundaries of endothelial cells. J Biol Chem 2000;275:19139-19145.
35. Blazar BR, Taylor PA, McElmurry R et al. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer. Blood 1998;92:3949-3959.
36. Beilhack A, Schulz S, Baker J et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood 2008;111:2919-2928.
37. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253-257.
38. Nguyen VH, Zeiser R, Dasilva DL et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007;109:2649-2656.
39. Taylor PA, Panoskaltsis-Mortari A, Swedin JM et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004;104:3804-3812.
40. Venturi GM, Conway RM, Steeber DA et al. CD25+CD4+ regulatory T cell migration requires L-selectin expression: L-selectin transcriptional regulation balances constitutive receptor turnover. J Immunol 2007;178:291-300.
41. Schneider MA, Meingassner JG, Lipp M et al. CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 2007;204:735-745.
42. Miller MJ, Wei SH, Parker I et al. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 2002;296:1869-1873.
43. Stoll S, Delon J, Brotz TM et al. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 2002;296:1873-1876.
44. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154-159.
45. Bachmann MF, Kopf M, Marsland BJ. Chemokines: More than just road signs. Nat Rev Immunol 2006;6:159-164.
46. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-3001.
47. Gao J, Dennis JE, Muzic RF et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20.
48. Rüster B, Göttig S, Ludwig RJ et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006;108:3938-3944.
49. Sordi V, Malosio ML, Marchesi F et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005;106:419-427.
50. Phinney DG, Prockop DJ. Concise review: Mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair- current views. STEM CELLS 2007;25:2896-2902.